Schwab Charles Investment Management Inc. Buys New Holdings in Ovid Therapeutc (OVID)
Schwab Charles Investment Management Inc. bought a new stake in Ovid Therapeutc (NASDAQ:OVID) during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund bought 14,500 shares of the company’s stock, valued at approximately $153,000. Schwab Charles Investment Management Inc. owned approximately 0.06% of Ovid Therapeutc as of its most recent SEC filing.
COPYRIGHT VIOLATION WARNING: This news story was first published by Daily Political and is the property of of Daily Political. If you are viewing this news story on another publication, it was illegally copied and reposted in violation of United States and international copyright and trademark law. The legal version of this news story can be viewed at https://www.dailypolitical.com/2017/11/14/schwab-charles-investment-management-inc-buys-new-holdings-in-ovid-therapeutc-ovid.html.
Separately, Zacks Investment Research raised shares of Ovid Therapeutc from a “sell” rating to a “hold” rating in a report on Tuesday, October 17th. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. Ovid Therapeutc currently has an average rating of “Buy” and an average price target of $23.50.
Shares of Ovid Therapeutc (NASDAQ:OVID) opened at $9.66 on Tuesday. Ovid Therapeutc has a fifty-two week low of $5.28 and a fifty-two week high of $15.93.
Ovid Therapeutc (NASDAQ:OVID) last issued its earnings results on Thursday, November 9th. The company reported ($0.38) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.54) by $0.16. analysts expect that Ovid Therapeutc will post -4.61 earnings per share for the current fiscal year.
In other news, CEO Jeremy M. Levin bought 15,334 shares of the stock in a transaction dated Friday, August 25th. The shares were acquired at an average price of $7.15 per share, with a total value of $109,638.10. Following the completion of the acquisition, the chief executive officer now directly owns 4,601,529 shares in the company, valued at $32,900,932.35. The acquisition was disclosed in a filing with the SEC, which can be accessed through the SEC website.
About Ovid Therapeutc
Ovid Therapeutics Inc (Ovid) is a biopharmaceutical company. The Company is engaged in developing medicines for patients and families living with rare neurological disorders. Its lead drug candidate is OV101. The Company’s second lead drug candidate is OV935. OV101 (gaboxadol) is a delta-selective GABAA receptor agonist.
Receive News & Ratings for Ovid Therapeutc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ovid Therapeutc and related companies with MarketBeat.com's FREE daily email newsletter.